Connor, Clark & Lunn Investment Management (CC&L)
DYN icon

Connor, Clark & Lunn Investment Management (CC&L)’s Dyne Therapeutics DYN Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-41,157
Closed -$1.48M – 1456
2024
Q3 		$1.48M Buy
+41,157
New +$1.64M 0.01% 751
2023
Q2 		– Sell
-21,010
Closed -$242K – 1365
2023
Q1 		$242K Buy
+21,010
New +$273K ﹤0.01% 1056

Other funds holding DYN

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s DYN Position: Q4 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Dyne Therapeutics (DYN) in Q4 2024, closing a stake of 41,157 shares — an estimated $1.48M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in DYN in Q1 2023 and held it in 2 quarters. The position peaked at $1.48M in Q3 2024. 200 funds tracked by Wall St. Rank hold DYN as of Q4 2024.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Dyne Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 41,157 Dyne Therapeutics shares in Q4 2024, an estimated $1.48M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Dyne Therapeutics in Q1 2023 and held it in 2 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Dyne Therapeutics position peaked at $1.48M in Q3 2024.
  • 200 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q4 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2024, filed 10 Feb 2025.